Silence Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.03.23	Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results (Businesswire)
02.03.23	Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023 (Businesswire)
08.02.23	Silence Therapeutics to Present at SVB Securities Global Biopharma Conference (Businesswire)
06.02.23	Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer (Businesswire)
12.01.23	Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates (Businesswire)
03.01.23	Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
10.11.22	Silence Therapeutics Reports Third Quarter 2022 Results (Businesswire)
09.11.22	Silence Therapeutics to Present at Jefferies London Healthcare Conference (Businesswire)
05.11.22	Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting (Businesswire)
29.09.22	Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia (Businesswire)
27.09.22	Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference (Businesswire)
08.09.22	Silence Therapeutics to Participate in September Investment Conferences (Businesswire)
08.09.22	Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera (Businesswire)
12.08.22	Silence Therapeutics Announces Pricing of Underwritten Offering (Businesswire)
02.06.22	Silence Therapeutics to Present at Jefferies Healthcare Conference (Businesswire)
18.05.22	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference (Businesswire)
16.05.22	Silence Therapeutics Reports First Quarter 2022 Results (Businesswire)
25.04.22	Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration (Businesswire)
06.04.22	Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference (Businesswire)
03.04.22	Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a) (Businesswire)
03.04.22	Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting (Businesswire)
23.03.22	Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501 (Businesswire)
17.03.22	Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results (Businesswire)
02.03.22	Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022 (Businesswire)
21.02.22	Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer (Businesswire)
09.02.22	Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a) (Businesswire)
26.01.22	Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Silence Therapeutics PLC

Aktien Top/Flop

Meistgelesene Nachrichten